Serum soluble lectin‐like oxidized low‐density lipoprotein receptor‐1 as a biomarker of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Objective Delayed cerebral ischemia (DCI) greatly contributes to the high morbidity and mortality of aneurysmal subarachnoid hemorrhage (aSAH) patients. Expression of lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) was substantially raised in the basilar arterial wall of SAH rabbits. We attempted to ascertain the relationship between serum soluble LOX‐1 (sLOX‐1) levels and the occurrence of DCI after aSAH. Materials and methods We enrolled 125 aSAH patients and 125 healthy controls. Serum sLOX‐1 levels were quantified using commercial enzyme‐linked immunosorbent assay kit. The relationship between sLOX‐1 levels and DCI was analyzed utilizing the multivariate logistic regression analysis. Results Serum sLOX‐1 levels were significantly higher in stroke patients than in controls (median: 1,450.2 vs. 445.7 pg/ml, p 1,450.2 pg/ml, WFNS scores and modified Fisher scores were the independent predictors of DCI. Under receiver operating characteristic curve, serum sLOX‐1 levels exhibited a significant discriminatory capability (area under curve 0.825, 95% confidence interval 0.747–0.887). The predictive power of serum sLOX‐1 levels was similar to those of WFNS scores and modified Fisher grade (both p > .05). Moreover, serum sLOX‐1 levels significantly improved their predictive capability (both p
There is a substantial elevation in serum sLOX‐1 levels after aSAH. There is an intimate correlation of serum sLOX‐1 levels with hemorrhagic severity. There is an independent association of serum sLOX‐1 levels with delayed cerebral ischemia.